fda approval in crc, priority review in hcc, encouraging data in myeloma trial, and more
Published 6 years ago • 124 plays • Length 7:07
Download video MP4
Download video MP3
Similar videos
-
11:50
fda approval in myeloma, priority review in dlbcl, application accepted of a biosimilar, and more
-
6:27
fda approval in myeloma, priority review in all, and 2017 gu cancers symposium highlights
-
10:08
fda approvals in myeloma and attp, priority review designations in rcc and hnscc, and more
-
12:53
fda approval in sclc, partial hold in myeloma trials, nccn guideline update in crc, and more
-
8:45
fda approvals in gvhd, crc, and aml, a priority review in mcl, and more
-
9:02
fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more
-
10:08
fda approval in waldenstrom macroglobulinemia, priority review and snda in myeloma, and more
-
10:55
fda approval in myeloma, label update in her2 breast cancer, and more
-
8:12
fda approvals in hcc, sclc, and nsclc, priority review in rare blood cancer, and more
-
8:29
fda approval in multiple myeloma, priority reviews in dlbcl and myeloma, and more
-
5:55
fda approval in myeloma, breakthrough designations in rcc and aplastic anemia, and more
-
10:20
fda approvals in myeloma and thyroid cancer, priority review and nda in nsclc, and more
-
9:57
fda approvals in fl and rcc, breakthrough designation in myeloma, and more
-
10:46
fda approval in all, priority reviews in cml and breast cancer, and more
-
9:45
fda approval of a biosimilar, promising data in myeloma and gbm, and more
-
6:02
fda approvals, breakthrough designations, priority reviews, and more
-
0:31
preview: fda approval in rare leukemias, priority reviews in msi-h cancers and mcc, and more
-
6:56
fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
-
10:01
fda approval in ctcl, breakthrough therapy designation in crc, and more
Clip.africa.com - Privacy-policy